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Abstract
Background: Anti-tumor necrosis factor alpha (anti-TNF) drugs are very effective for the treatment of rheumatoid
arthritis but may increase the risk of serious bacterial infections. We assessed the association between the risk of
serious skin and soft tissue infections (SSSTI) and the use of these agents in rheumatoid arthritis patients (RA).
Methods: We conducted a nested case–control study among rheumatoid arthritis patients in the Veterans
Integrated Service Network 20 from 2000–2008. We identified rheumatoid arthritis patients with SSSTI, matched
them to three sets of RA controls and used conditional logistic regression to compare the risk of SSSTI between
patients treated and those not treated with an anti-TNF drug, after adjusting for known confounders and important
covariates. Limited by the design, we could not assess (absolute) risk but only relative risk in terms of association.
Results: Among the 97 cases and 291 controls, 90 percent were male, 62 percent white, with a mean age of
63 years. Twenty percent received anti-TNF drugs during the study period. Thirty-nine percent of cases and 15
percent of controls died, (OR 3.5, 95% CI: 2.033, 6.11, p <0.01). Diabetes mellitus (37%), kidney disease (16%) and a
history of skin infections (27%) were common among cases. Based on conditional logistic regression, anti-TNF use
was not significantly associated with skin and soft tissue infections (OR 1.1, 95% CI: 0.61-2.03, p = 0.92). However,
patients with diabetes mellitus (OR 2.5, 95% CI: 1.53-4.13, p = 0.01) or a prior history of skin infection (OR 5.7, 95%
CI: 2.87-11.43, p <0.01) were more likely to have skin and soft tissue infections.
Conclusion: Use of anti-TNF therapy among RA patients was not associated with an increased risk of SSSTI, but
patients with diabetes mellitus and those with a history of prior skin infection were significantly more likely to have
SSSTI and mortality was higher among cases than controls in this veteran cohort.
Keywords: Infectious skin diseases, Tumor necrosis factor-alpha, Anti-TNF therapy, Arthritis, Rheumatoid
Background
More than 2.5 million patients in the U.S. have rheuma-
toid arthritis (RA), [1] and world wide the prevalence is
estimated to be 1% of the population [2]. RA is a chronic
inflammatory symmetrical polyarthritis and if untreated
results in joint erosions, joint deformities and significant
disability. Extra-articular manifestations including sub-
cutaneous nodules, pulmonary manifestations, vasculitis,
and inflammatory eye disease may be particularly chal-
lenging to treat. Early diagnosis and recent advances in
RA treatment may prevent disease progression and
improve long-term outcomes [3]. RA patients have an
increased lifetime risk for cardiovascular disease [4] and
are at greater risk of developing infections [5-7]. The
problem of increased infections and higher rates of mor-
tality from infections in RA patients compared to indi-
viduals without RA has been well described in the past
decade. A pivotal cohort study evaluating RA patient
data for up to 15 years found a twofold greater risk of
infection in patients with RA compared to those without
RA, in particular serious infections of the lung, skin,
bone, and joint [8]. Specific causes for the high rate of
infections remain indistinct but having compromised
immune systems may put this cohort at substantial risk
for severe complications [9].
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Increased risk of skin and soft tissue infections in RA patients
Skin and soft tissue infections (SSSTI) represent an im-
portant cause of morbidity for RA patients [9].
Among the increased infections noted, SSSTI are a
leading cause of hospitalization and antibiotic drug use
[10-13]. A 2009 study to assess the prevalence of serious
infections among RA patients receiving anti-TNF ther-
apy found that 20.5 percent of the serious infections
identified were SSSTI [14].
SSSTI are difficult to treat in immosuppressed patients,
often become life threatening, and represent a substantial
public health burden [15,16]. The increase of SSSTI and
continuing escalation in methicillin-resistant staphylococ-
cus aureus rates andother serious infections raises the
possibility that increased infections among RA patients
and other autoimmune disease populations could be re-
lated to treatment with immunosuppressive agents.
Effect of immunosuppressive drugs on the risk of
infection in RA patients
A wide variety of drugs are used to minimize inflammation,
treat pain, and slow the progression of RA. Treatments
range from mild to aggressive therapies depending on the
severity of disease activity. Therapies for RA include non-
steroidal anti-inflammatory drugs (NSAIDs), corticoste-
roids, disease-modifying antirheumatic drugs (DMARDs),
and biologic agents including anti-TNF agents (drugs that
inhibit tumor necrosis factor-apha).
Nearly half of the RA patients in the United States
have received anti-TNF drugs [17]. Although anti-TNF
drug treatment is highly successful, studies conducted in
the past ten years indicate that the risk of developing a
serious infection is higher among patients taking these
drugs, potentially because of the resultant immunosup-
pression [6,18].
Does anti-TNF use in RA patients increase the risk of infection?
It remains unclear how immunosuppressive therapies
might influence the risk of SSSTI [8]. Numerous studies
have assessed the increased risk of infection among pa-
tients receiving anti- TNF drug therapy [16]. A small sys-
tematic review (9 trials) [19] and a lager meta-analysis
[20], both found an association between anti-TNF drug
treatment and an increase in all serious infections. In two
large retrospective cohort studies, including one con-
ducted among U.S. Veterans Administration Hospitals pa-
tients, [21] one found a slightly increased risk (HR 1.24)
between TNFi and hospitalized infection but it was of less
magnitude than that for prednisone and the other study
found no association [22].
Despite these studies, research into the increased rate
of serious infections in RA patients since the introduc-
tion of anti-TNF therapy in the U.S. is still limited [19].
Results across studies are inconsistent, establishing a
need for further research to identify potential risk factors
and better assess the safety of anti-TNF therapy. The in-
creasing trend in anti-TNF drug use to treat RA makes
investigating the association of biologics with serious
skin and soft tissue infections a clinically and epidemio-
logically important endeavor.
The high rate of mortality and co-morbidities among
patients in the Veterans Integrated Service Network
(VISN) makes understanding risk factors for serious in-
fections of particular significance for this at risk popula-
tion, yet there remains a scarcity of research specifically
investigating the association of SSSTIs in relation to
anti-TNF therapy in this cohort.
The objective of this study was to determine if anti-TNF
therapy is associated with an increased occurrence of serious
skin and soft tissue infections requiring hospitalization in pa-
tients with rheumatoid arthritis. Relatively little VA specific
data has been published on this topic and that this is a
unique population quite distinct from other RA populations
with regard to sex, socioeconomic class, and other factors.
Methods
Study design and population
We conducted a nested case–control study among RA
patients in the VISN 20 from 2000–2008 to evaluate
anti-TNF drug use and SSSTI requiring hospitalization
adjusting for known confounders and clinically important
covariates such as age, sex, ethnicity, other immunosup-
pressant drug use, co-morbidities, and other autoimmune
diseases. This study was approved by the Portland VA
Medical Center Institutional Review Board.
Patient cohort definition
RA cohort definition
The cohort for this study was comprised of patients in the
United States Veterans Integrated Service Network 20,
consisting of individuals who lived predominantly in
Washington, Oregon, and Idaho. We defined RA patients
as patients having at least one international classification
of disease (ICD-9) code for RA (714), documentation of a
rheumatology visit two or more times, and at least one
prescription fill for a disease-modifying anti-rheumatic
therapy (DMARD) during the study time-period (verified
by pharmacy codes indicating at least one prescription fill
for at least one drug used to treat RA).
Definition of terms and variables
Hospitalized SSSTI case finding and control selection
Cases and controls were derived from comparable
Veterans Administration (VA) populations Similar to
prior studies, we used frequency of rheumatology visits in
the 12 months prior to index date as a proxy for disease.
We identified cases of SSSTI as patients having an
inpatient SSSTI discharge codes validated to have high
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positive predictive value for disease [23,24] and enrolled
all cases meeting the predefined criteria. For each case, we
assigned an index date corresponding to the date of the
hospital discharge. The cases were matched with controls
identified as RA patients with an outpatient physician ser-
vice date within +/− 30 days of each case’s index date at
the same VA facility as the case’s SSSTI hospitalization.
Three sets of controls meeting this definition were ran-
domly matched to each case.
Drug exposure determination and covariate measures
We considered cases and controls as exposed to anti-TNF
agents if they filled a prescription for etanercept or adali-
mumab or received an infusion for infliximab in the 90 days
before the index date. To ascertain potential confounders,
we collected the following covariates for each case and con-
trol, (defined by presence of disease specific inpatient or
outpatient ICD-9 codes present prior to the index date dur-
ing the study time-period): a history of diabetes mellitus,
chronic kidney disease, neoplasm, chronic bronchitis,
gastro esophageal reflux disease, human immunodeficiency
virus infection, chronic liver disease, Crohn’s disease,
ulcerative colitis, ankylosing spondylitis, uveitis, psoriatic
arthritis and prior SSSTI (ICD-9 record of SSSTI anytime
prior to study period) and a history of prior hospitalization
for infections. Concomitant medications assessed included
use of methotrexate, prednisone, azathioprine, leflunomide,
hydroxychlorquine, and sulfasalazine within 30 days of the
index date as well as prednisone use in the six months
prior to the index date and antibiotic use 90 days prior to
the index date. Medication use was defined by at least one
record of pharmacy fill during the study period within the
specified time frames for each medication.
Statistical analysis
We compared differences in covariates among cases and
controls using Fisher’s exact tests for categorical vari-
ables, and two-sample t-tests for continuous variables.
We used conditional logistic regression to evaluate the
association of SSSTI with covariates and specifically im-
munosuppressive drug use. Variables with a univariate
association with SSSTI with a p-value ≤ 0.25 and vari-
ables identified a priori as clinically and epidemiologi-
cally important independent covariates were considered
for building a conditional logistic regression multivariate
model [25]. We performed step-wise backward elimin-
ation and included immunosuppressive use and all other
variables with α ≤ 0.05 in our final model. Statistical ana-
lyses were conducted using SAS version 9.2 (SAS Insti-
tute Inc., Cary, N.C. 2008).
Results
We identified 97 cases and 291 controls from the entire
cohort of 6,305 RA patients in VISN 20 during the study
period. Cases and controls were similar with regard to
key prognostic factors for disease severity and did not
differ significantly with regard to age, race, and gender
or other demographic characteristics. Most patients were
male (92% cases and 89% controls) and white (77% cases
and 67% controls); with a mean age of 63 years for cases
and 61 years for controls (p > 0.05 for all baseline com-
parisons). Ninety-five percent of cases and 87 percent of
controls were 50 years old or greater. The average num-
ber of rheumatology clinical visits was similar for cases
and controls; 35 percent of cases and 41 percent of con-
trols had greater than 15 rheumatology clinical visits in
the 12 months prior to the index date suggesting cases
and controls had comparable RA disease activity.
Over the entire study time period 30 percent of cases
and 24 percent of controls were prescribed anti-TNF drugs
at least one time prior to the case’s index date. Diabetes
mellitus (37%), kidney disease (16%) and having a prior his-
tory of skin infections (27%) were common among cases,
but not among controls (18%, 4%, and 5% respectively).
Results of the univariate analysis of risk factors associ-
ated with developing SSSTI are presented in Table 1.
Based on univariate comparison of cases and controls,
diabetes mellitus, chronic kidney disease, chronic bron-
chitis, prior history of skin infection, pneumonia, dis-
charge 3 months prior, prednisone use within 30 days of
the index date and antibiotic use 90 days prior to the
index date were considered for multivariate model. Age
and race were also included in the initial multivariate
model to assess potential confounding.
Multivariate models were built to examine the associ-
ation between anti-TNF drug use and SSSTI, results of the
final model are presented in Table 2. Based on conditional
logistic regression, anti-TNF use was not significantly asso-
ciated with SSSTI (OR 1.1, 95% CI: 0.61-2.03, p = 0.92) but
patients with diabetes mellitus (OR 2.5, 95% CI: 1.53-4.13,
p < 0.01) or a history of skin infection (OR 5.7, 95% CI:
2.87-11.43, p < 0.01) were more likely to have SSSTI.
Eighty-three patients died during the study (39% cases
and 15% controls, OR 3.5, 95% CI: 2.03, 6.11, p <0.01).
A similar proportion of cases and controls had diabetes
mellitus and of the cases who died, 36.8% had diabetes
mellitus compared to 37.3% of cases who did not die.
However, cases who died were more likely to have prior
history of skin infection (40%) than cases who did not
die (19%) during the study period (OR 2.8, 95% CI: 1.13-
7.64, p = .02).
Discussion
We studied a large US Veterans cohort of RA patients
to evaluate whether SSSTI are associated with the use
of anti-TNF therapies. We found SSSTI cases were no
more likely to be recently exposed to anti-TNF therap-
ies than matched controls. However, we found strong
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associations between diabetes and SSSTIs, as well
as SSSTI and subsequent mortality independent of
DMARD therapy.
Based on previous studies in other patient populations,
we estimated that our study would reveal at least a two-
fold greater risk of serious skin and soft tissue infections
among VA hospital rheumatoid arthritis patients receiv-
ing anti - TNF drug therapy, yet we saw no significant
association between anti- TNF therapy and increased
SSSTI risk.
Table 1 Univariate analysis of covariates including patient drug exposures, comorbidities, and the association with
hospitalized SSSTI
Variable Case Control Odds Ratio 95% P-Value
N = 97 N = 291 Confidence
IntervalFrequency (Percent) Frequency (Percent)
MEDICATONS
Anti-TNF Drugs
Biologics 90 days before index date 19 (19.59) 53 (18.15) 1.107 0.604, 2.028 0.74
Biologics Anytime Before Index 29 (29.90) 70 (23.97) 1.388 0.815, 2.363 0.23
ETANERCEPT Anytime Before Index 16 (16.49) 42 (14.38) 1.184 0.631, 2.22 0.60
INFLIXIMAB IV Anytime Before Index 3 (3.09) 13 (4.45) 0.857 0.178, 4.126 0.85
ADALIMUMAB Anytime Before Index 1 (1.03) 7 (2.40) 0.404 0.47, 3.462 0.41
Monoclonals Only: INFLIXIMAB/ ADALIMUMAB 7 (7.22) 14 (4.79) 0.633 0.178, 2.245 0.48
Concomitant Medications
Methotrexate within 30 days of index date 20 (20.62) 89 (30.48) 0.578 0.325, 1.029 0.06
Prednisone within 30 days of index date 51 (52.58) 107 (36.64) 1.921 1.206, 3.058 <0.01
Prednisone 6 mo. prior to index date 56 (57.73) 144 (49.32) 1.447 0.898, 2.334 0.13
Azathioprine within 30 days of index date 3 (3.09) 4 (1.37) 2.250 0.504, 10.053 0.29
Leflunomide within 30 days of index date 7 (7.22) 25 (8.56) 0.819 0.345, 1.940 0.65
Hydroxychlorquine within 30 days of index date 23 (23.71) 84 (28.77) 0.784 0.462, 1.330 0.36
Sulfasalazine within 30 days of index date 6 (6.19) 38 (13.01) 0.454 0.187, 1.104 0.08
Antibiotic use 90 days prior to index date 86 (88.66) 51 (17.47) 44.984 16.41, 123.28 <0.01
Concomitant Inflammatory Diseases
Psoriasis 10 (10.31) 33 (11.30) 0.892 0.411, 1.934 0.77
Crohns† 3 (3.09) 3 (3.09) 2.805 0. 564, 13.962 0.21
Ulcerative Colitis† 3 (3.09) 4 (1.37) 2.121 0.473, 9.514 0.33
Ankylosing Spondylitis† 4 (4.12) 7 (2.40) 1.714 0.502, 5.86 0.39
Uveitis† 2 (2.06) 0 (0.00) 0.138 - ∞, 0.573 0.13
Co-morbidities
Diabetes mellitus 36 (37.11) 53 (18.15) 2.514 1.528, 4.134 <0.01
Chronic Kidney Disease 15 (15.46) 11 (3.77) 4.558 1.981, 10.487 <0.01
Neoplasm 9 (9.28) 12 (4.11) 2.464 0.993, 6.116 0.50
Chronic Bronchitis 44 (45.36) 81 (27.74) 2.133 1.327, 3.429 0.01
Gastroesophageal Reflux 36 (37.11) 94 (32.19) 1.282 0.777, 2.114 0.33
HIV† 0 (0.00) 1 (0.34) 0.333 0.009, ∞ 1.00
Prior History of Skin Infection (SSSTI) 26 (26.80) 17 (5.82) 5.729 2.870, 11.434 <0.01
Discharge 3 Months Prior 14 (14.43) 20 (6.85) 2.245 1.098, 4.590 0.03
Chronic Liver Disease† 2 (2.06) 0 (0.00) 0.167 -∞, 0.7732 0.17
Other Bacterial Infections
Pneumonia† 4 (4.12) 1 (0.34) 12 1.341, 107.63 0.03
Septic Arthritis† 1 (1.03) 1 (1.03) .333 0.004, 26.166 0.89
†Cell count less than 5, Exact Analysis Used.
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In relation to existing research, our findings differ from
earlier studies that reported an association between anti-
TNF drug treatment and an increase in all serious infec-
tions in RA patients [19,20]. Conversely, recent studies
reported similar results to ours, and found no association
between anti-TNF therapy and increased risk of infection
in RA patients [22]. Another large retrospective study
conducted among elderly RA patients, using data from
1995 to 2003, also did not find an increase in serious in-
fections when comparing patients receiving anti-TNF
therapy to those receiving methotrexate [26].
One of the most recent studies was conducted in a
U.S. VA patient population and evaluated patient data
up to 2005. In our study we analyzed data from a
broader range of years in order to capture information
from the period prior to 2004 (when anti-TNF drugs
therapy became wide spread in the U.S.), as well as data
up to 2008 (four years after anti-TNF drugs prescription
was common) [27] and to enrich the number of cases of
patients exposed and not exposed to anti-TNF.
Demographic and patient characteristics unique to the
VA hospital population (being predominantly white,
male, and older, and having a high number of comorbid
conditions), as well as other limitations of the study de-
sign, including the small sample size, may be contribut-
ing factors to the difference in results between previous
studies and ours.
The unique characteristics of this patient population
may also limit the ability to generalize our results to pa-
tients outside the VA hospital network. In the VA cohort,
approximately 2 percent of the RA patients were identi-
fied as having had a SSSTI. The prevalence of SSSTI we
identified was lower than rates reported by other studies
of anti-TNF drug use and all serious infections in RA pa-
tients, however, many of the studies evaluated all skin in-
fections, rather than limiting to serious infections that
result in hospitalization. Additionally, data for patients re-
ceiving acute care outside of the VISN20 for SSSTI were
not captured by our study, which may account for the
lower percentage of identified cases.
It is important to note that in the VA patient population
studied, anti- TNF drugs were prescribed less than 20
percent of the time, while in the general population as
many as 40 percent of rheumatoid arthritis patients re-
ceive anti-TNF drug treatment [17]. The prescribing pat-
terns for anti-TNF treatment may be influenced by the
high rates of co-morbidities present among these patients
and by VA prescribing guidelines. In this VA patient
population, average anti-TNF drug use over the entire
study period was 16.7 percent for cases and 17.5 percent
for controls.
Lastly, other studies have reported a significant associ-
ation with prednisone use as a risk factor for infection lead-
ing to hospitalization [21,28]. In our multivariate analysis,
prednisone use was not statistically significant; however,
our study only evaluated the risk for SSSTI, as opposed to
evaluating all major types of infection, and this, as well as
the small sample size or possible dose–response relation-
ships may have limited our power to detect an effect.
Although we observed no association between anti-
TNF or other immunosuppressant therapy and SSSTI,
we did identify hospitalized SSSTI as a strong risk factor
for death during the study time-period. An average of 29
percent of cases died within 1 year of the index date
compared to 10 percent of controls.
The higher proportion of cases who died than controls
may be a marker for sicker patients with higher rates of
co-morbidities. Attention was paid to potential con-
founding variables that may be indicators of severity of
disease and increased risk of infection, such as the num-
ber of RA office visits in the year prior to infection, and
the need for prednisone use, all of which are factors that
may contribute to confounding by indication since sicker
patients (those more likely to get infections) are less
likely to be treated with these drugs. We attempted to
control for this by using proxies for RA severity, but it is
possible that we did not fully control for it.
Despite intrinsic limitations to our case–control study
design, we attempted to reduce bias and confounding in
several ways. We used validated ICD 9 codes with proven
high positive predictive values for disease to identify cases
of SSSTI, which may reduce misclassification bias [23], and
matched cases to three sets of comparable controls to miti-
gate the impact of potential confounders. To minimize the
Table 2 Results of the final multivariate model of patient drug exposures and comorbidities and their association with
hospitalized SSSTI
Variable Case Control Odds
Ratio
95% Adjusted
p valueN = 97 N = 291 Confidence Interval
Frequency (Percent) Frequency (Percent)
Anti-TNF drug exposure 19 (19.59) 53 (18.15) 1.107 0.604, 2.028 0.92
Diabetes mellitus 36 (37.11) 53 (18.15) 2.514 1.528, 4.134 <0.01
Prior SSSTI 26 (26.80) 17 (5.82) 5.729 2.870, 11.434 <0.01
Multivariate adjustment for RA severity, diabetes mellitus, chronic kidney disease, chronic bronchitis, prior history of skin infection, pneumonia, discharge
3 months prior, prednisone use within 30 days of the index date and antibiotic use 90 days prior to the index. Age and race were also included in the initial
multivariate model to assess potential confounding.
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risk of confounding by indication, we analyzed as indicators
of disease severity the erythrocyte sedimentation rate, the
number of RA clinic visits, and the need for prednisone
use, however, propensity scores for severity of RA for this
population were not available since the VA hospital net-
work does not systematically collect this data. Although
our RA cohort size was reasonably large, a fairly small
number of SSSTI cases were identified resulting in a rela-
tively small sample size for our case–control analysis.
In this patient cohort, significant predictors of serious
skin and soft tissue infections included diabetes mellitus
and having a prior history of skin infection. The impact
of these findings suggests that patients in the VA cohort
with a history of prior skin infection or diabetes mellitus
are at elevated risk for serious skin and soft tissue infec-
tions and hospitalization. The increased mortality among
cases indicates that intervention and careful monitoring
of these patients may be important.
Conclusion
The findings of our research on the risk of serious skin
and soft tissue infection in this patient group highlights
the need for further study to provide insight into im-
proving clinical care and preventing future complica-
tions and morbidity in this patient population.
SSSTI were significantly associated with diabetes mel-
litus and history of skin infection but not associated with
anti-TNF use in the VISN 20 RA patient cohort. How-
ever, patients with SSSTI were much more likely to die
than matched controls. These findings highlight the
need to better understand trends in diabetes and SSSTI
cares among US veteran’s and argue for further evalu-
ation of specific co-morbidities and other factors that
could be associated with SSSTI related mortality.
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